Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T
→ Regeneron and Sanofi‘s Dupixent — a king in the eczema therapy sector — has cinched its third type 2 inflammatory disease approval in the EU …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
